The Latest Cardiac and Vascular News
BEDFORD, Mass., April 15, 2025 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Daniel Davis to its Board of Directors. Mr. Davis is Chief Strategy Officer at Imperative…
BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System. The Tembo Embolic System is a bioresorbable1 embolization…
Clinical investigators achieve significant milestone by enrolling 150 patients with hypervascular tumors in pivotal randomized study. BEDFORD, Mass., May 14, 2024 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company focused on developing liquid embolics for peripheral…
BEDFORD, Mass., Aug. 15, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the closing of a $30 million financing round. This financing round was led by new investor, Delos Capital, with continued participation from the investor syndicate of Excelestar Ventures, Ascension Ventures, Catalyst Health […]
Pivotal study to evaluate Embrace™ Hydrogel Embolic System for the embolization of arterial bleeds in the peripheral vasculature BEDFORD, Mass., Jan. 10, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patient in the HALT Study1 for the treatment of peripheral […]
BEDFORD, Mass., July 26, 2022 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluatedi the […]
Prospective multicenter study evaluated the safety and efficacy of a PEG-based liquid embolic in treating hypervascular tumors BEDFORD, Mass., March 15, 2022 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of resultsi from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) […]
